Tebentafusp

N/A

Report date: 2026/04/15 20:02:38
First In Class

Base Information

Drug NameTebentafusp
Drug Alias NameMonoclonal T cell receptor anti-CD3 scFv fusion proteinTebentafusp-tebnKIMMTRAKImmTAC-gp-100IMC-gp-100 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-chain FV antibody fragment (scFv)Biologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > T cell engagers
Mechanisms of ActionMelanocyte protein PMEL modulatorsT cell surface glycoprotein CD3 modulatorsCD3 T-cell engagers
TargetsMelanocyte protein PMELT cell surface glycoprotein CD3
Therapy Area/IndicationsUveal melanomaSkin MelanomaMelanoma
Global Approved IndicationsUveal melanoma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2022/01/25
Country/TerritoryBelgiumCanadaUnited States +[16] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesImmunocore Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMedison PharmaImmunocore Holdings PLCImmunocore Ltd +[5] 
Inactive CompaniesUniversity Of Southern CaliforniaUniversity Of MiamiNational Cancer Institute +[7] 
Active IndicationsUveal melanomaSkin Melanoma
Inactive IndicationsMelanoma

Other Information

ATC CodeL01XX
Related LinksWikipediaDrugBank